without any evidence of a pre-existing, less-malignant precursor lesion. Patients typically present after a short clinical history (usually less than 3 months).[4]Treatment is palliative and includes
without any evidence of a pre-existing, less-malignant precursor lesion. Patients typically present after a short clinical history (usually less than 3 months).[4]Treatment is palliative and includes
Frontiers in the treatment of glioblastoma: Past, present and emerging Taskeen IqbalJanjua, ...AmiraliPopat, inAdvanced Drug Delivery Reviews, 2021 Abstract Glioblastoma(GBM) is one of the most aggressive cancers of the brain. Despite extensive research over the last several decades, the survival...
Global glioblastoma multiforme (gbm) treatment market size is expected to reach $3.66 Bn by 2028 at a rate of 10.3%, segmented as by treatment, surgery, radiation therapy, chemotherapy, targeted therapy
We attributed it to the adoption of a new standard of neurosurgical treatment on the basis of neurosurgical multimodal technologies. Even though the prognosis of glioblastoma patients remains poor, gradual progress is being made.doi:10.1080/02688697.2021.1907306Chen Luo...
In pursuit of novel therapeutic targets for GBM treatment, we selected peptides where our predictive results indicated that mutations would not disrupt epitope presentation, thereby maintaining a specific CD8 T cell immune response. These peptides hold potential for future GBM interventions, including ...
Glioblastoma multiforme (GBM) is the most aggressive primary central nervous system (CNS) tumor, and treatment for GBM is regarded as the most challenging ... Y Ma,Z Yang,K Huntoon,... - 《Advanced Therapeutics》 被引量: 0发表: 2021年 加载更多来源...
Chemotherapy seems to have been dropped from the therapeutic arsenal for GB, probably because current research is focusing on new treatment modalities like immunotherapy and targeted therapy. Nonetheless, several agents are being evaluated, including lisavanbulin (BAL101553), a microtubule-tar...
we find that inhibiting β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with MK-8931 potently reprograms pTAMs into sTAMs and promotes macrophage phagocytosis of glioma cells; moreover, low-dose radiation markedly enhances TAM infiltration and synergizes with MK-8931 treatment to suppress...
In conclusion, NDV-LaSota enhanced the cytotoxicity of TMZ not only by down-regulating the AKT–mTOR signaling pathway but also by activating AMPK. This effect was confirmedin vitroandin vivo. This novel combination treatment could offer meaningful new choices for patients with advanced GBM. ...